The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
Open accessAbstract
Background: Inflammatory bowel disease (IBD) is commonly treated with immunomodulators such as azathioprine and 6-mercaptopurine (6-MP). Studies examining lymphoma risk in IBD patients treated with these medications have been underpowered and have yielded conflicting conclusions. Aims: The purpose of this meta-analysis was to provide a more precise estimate of the relative risk of lymphoma among IBD patients treated with azathioprine or 6-MP. Methods: Studies were included if they were English language, full article, cohort studies specifically designed to evaluate cancer as an adverse outcome of treatment with azathioprine or 6-MP. Pooled standardised incidence ratios were calculated to estimate the relative risk of lymphoma associated with therapy. Heterogeneity was assessed using Poisson regression. Sensitivity analyses examined the influence of individual studies on risk estimate and heterogeneity statistics. Results: Six studies were identified that met our inclusion criteria. When the data were combined across all studies, the pooled relative risk was 4.18 (95% confidence interval 2.07–7.51; 11 observed cases, 2.63 expected). Sensitivity analysis showed that exclusion of any one study had a relatively small effect on the pooled relative risk estimate (range 3.49–5.21) but excluding either the study with the highest or lowest estimated relative risk eliminated the statistically significant heterogeneity. Conclusions: Our data suggest an approximate fourfold increased risk of lymphoma in IBD patients treated with azathioprine/6-MP. The increased risk of lymphoma could be a result of the medications, the severity of the underlying disease, or a combination of the two.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Cancer Incidence in Five Continents
(1966) · doi:10.1007/978-3-642-85849-9 · Cited by 5,936
Cancer risk in patients with inflammatory bowel disease: A population-based study
Bernstein, C. N., Blanchard, J. F., Kliewer, E., & Wajda, A. (2001) · Cancer · doi:10.1002/1097-0142(20010215)91:4<854::aid-cncr1073>3.0.co;2-z · Cited by 1,165
Statistical methods in cancer research
Gardner, B. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1170 · Cited by 777
Incidence of non-hodgkin lymphoma in kidney and heart transplant recipients
Opelz, G., & Henderson, R. (1993) · The Lancet · doi:10.1016/s0140-6736(05)80084-4 · Cited by 648
Crohn's disease and cancer: A population-based cohort study
Persson, P.-G., Karlén, P., Bernell, O., Leijonmarck, C.-E., Broström, O., Ahlbom, A., & Hellers, G. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90807-9 · Cited by 306
Inflammatory bowel disease is not associated with an increased risk of lymphoma
Lewis, J. D., Bilker, W. B., Brensinger, C., Deren, J. J., Vaughn, D. J., & Strom, B. L. (2001) · Gastroenterology · doi:10.1053/gast.2001.28703 · Cited by 296
Self-citationSilman, A. J., Petrie, J., Hazleman, B., & Evans, S. J. (1988) · Annals of the Rheumatic Diseases · doi:10.1136/ard.47.12.988 · Cited by 276
Farrell, R. J., Ang, Y., Kileen, P., O'Briain, D. S., Kelleher, D., Keeling, P. W. N., & Weir, D. G. (2000) · Gut · doi:10.1136/gut.47.4.514 · Cited by 260
Cited by
Kornbluth, A., & Sachar, D. B. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2009.727 · Cited by 2,023
Inflammatory bowel disease: clinical aspects and established and evolving therapies
Baumgart, D. C., & Sandborn, W. J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60751-x · Cited by 1,920
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Guidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Beaugerie, L., Brousse, N., Bouvier, A. M., Colombel, J. F., Lémann, M., Cosnes, J., Hébuterne, X., Cortot, A., Bouhnik, Y., Gendre, J. P., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61302-7 · Cited by 1,115
Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn’s disease
Ruemmele, F. M., Veres, G., Kolho, K. L., Griffiths, A., Levine, A., Escher, J. C., Amil Dias, J., Barabino, A., Braegger, C. P., Bronsky, J., et al. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.04.005 · Cited by 1,083
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
Toruner, M., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., Orenstein, R., Sandborn, W. J., Colombel, J., & Egan, L. J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.01.012 · Cited by 1,017
Beaugerie, L., Seksik, P., Nion–Larmurier, I., Gendre, J., & Cosnes, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.019 · Cited by 860
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Cancers Complicating Inflammatory Bowel Disease
Beaugerie, L., & Itzkowitz, S. H. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1403718 · Cited by 678
Travis, S. P. L., Stange, E. F., Lémann, M., Öresland, T., Chowers, Y., Forbes, A., D’Haens, G., Kitis, G., Cortot, A., Prantera, C., et al. (2006) · Gut · doi:10.1136/gut.2005.081950b · Cited by 597
Lemaitre, M., Kirchgesner, J., Rudnichi, A., Carrat, F., Zureik, M., Carbonnel, F., & Dray-Spira, R. (2017) · JAMA · doi:10.1001/jama.2017.16071 · Cited by 575
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
Timmer, A., Patton, P. H., Chande, N., McDonald, J. W., & MacDonald, J. K. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000478.pub4 · Cited by 528
Siegel, C. A., Marden, S. M., Persing, S. M., Larson, R. J., & Sands, B. E. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.01.004 · Cited by 511
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Nakase, H., Uchino, M., Shinzaki, S., Matsuura, M., Matsuoka, K., Kobayashi, T., Saruta, M., Hirai, F., Hata, K., Hiraoka, S., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01784-1 · Cited by 505
Kotlyar, D. S., Osterman, M. T., Diamond, R. H., Porter, D., Blonski, W. C., Wasik, M., Sampat, S., Mendizabal, M., Lin, M. V., & Lichtenstein, G. R. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2010.09.016 · Cited by 477
Risk for colorectal cancer in ulcerative colitis: Changes, causes and management strategies
Lakatos, P. L., & Lakatos, L. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.3937 · Cited by 442
Lichtenstein, G. R., Abreu, M. T., Cohen, R., & Tremaine, W. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.048 · Cited by 417
Kotlyar, D. S., Lewis, J. D., Beaugerie, L., Tierney, A., Brensinger, C. M., Gisbert, J. P., Loftus, E. V., Peyrin-Biroulet, L., Blonski, W. C., Van Domselaar, M., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.015 · Cited by 414
Self-citationImmunosuppressive Therapy and Malignancy in Organ Transplant Recipients: A Systematic Review
Gutierrez-Dalmau, A., & Campistol, J. M. (2007) · Drugs · doi:10.2165/00003495-200767080-00006 · Cited by 408
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub3 · Cited by 402
Jess, T., Riis, L., Vind, I., Winther, K. V., Borg, S., Binder, V., Langholz, E., Thomsen, O. S., & Munkholm, P. (2007) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20036 · Cited by 394
Turner, D., Levine, A., Escher, J. C., Griffiths, A. M., Russell, R. K., Dignass, A., Dias, J. A., Bronsky, J., Braegger, C. P., Cucchiara, S., et al. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3182662233 · Cited by 382
The epidemiology of inflammatory bowel disease
Burisch, J., & Munkholm, P. (2015) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1014407 · Cited by 365
Cancer in inflammatory bowel disease
Xie, J., & Itzkowitz, S. H. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.378 · Cited by 328
ECCO Guidelines on Inflammatory Bowel Disease and Malignancies
Gordon, H., Biancone, L., Fiorino, G., Katsanos, K. H., Kopylov, U., Al Sulais, E., Axelrad, J. E., Balendran, K., Burisch, J., de Ridder, L., et al. (2023) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac187 · Cited by 317
120 Crohn's Disease: Factors Associated with Exposure to High Levels of Diagnostic Radiation
Desmond, A. N., O'Regan, K. N., Curran, C., McWilliams, S., Maher, M. M., & Shanahan, F. (2008) · Gastroenterology · doi:10.1016/s0016-5085(08)60102-x · Cited by 307
Chaparro, M., Ordás, I., Cabré, E., Garcia-Sanchez, V., Bastida, G., Peñalva, M., Gomollón, F., García-Planella, E., Merino, O., Gutiérrez, A., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/mib.0b013e318281f28f · Cited by 297
Dassopoulos, T., Sultan, S., Falck–Ytter, Y. T., Inadomi, J. M., & Hanauer, S. B. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.046 · Cited by 297
Predictors of severe Crohn's disease
Loly, C., Belaiche, J., & Louis, E. (2008) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520801957149 · Cited by 289
Hyams, J., Damaraju, L., Blank, M., Johanns, J., Guzzo, C., Winter, H. S., Kugathasan, S., Cohen, S., Markowitz, J., Escher, J. C., et al. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.11.026 · Cited by 286
Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
Feagan, B. G., Greenberg, G. R., Wild, G., Fedorak, R. N., Paré, P., McDonald, J. W. D., Cohen, A., Bitton, A., Baker, J., Dubé, R., et al. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.06.007 · Cited by 285
Treatment of inflammatory bowel disease: A review of medical therapy
Kozuch, P. L., & Hanauer, S. B. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.354 · Cited by 261
Treatment of neuromyelitis optica: review and recommendations
Kimbrough, D. J., Fujihara, K., Jacob, A., Lana-Peixoto, M. A., Isabel Leite, M., Levy, M., Marignier, R., Nakashima, I., Palace, J., de Seze, J., et al. (2012) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2012.06.002 · Cited by 260
Systematic review with meta-analysis: inflammatory bowel disease in the elderly
Gisbert, J. P., & Chaparro, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12616 · Cited by 158
Metadata
- Authors
- Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C., & Lewis, J. D.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2005-07-11
- Volume
- 54
- Issue
- 8
- Pages
- 1121-1125
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2148298419
- Cited by
- 808
- References
- 18
- FWCI
- 24.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.